Domestic Innovation Drugs Strengthen Global Competitiveness, GF CSI Innovative Drugs Industry ETF (515120) Up 0.30% in Morning Trading

NewTimeSpace News - As of 10:05 on January 9, 2026, Innovation Drug ETF (515120) rose 0.30%, with the latest price at 0.66 yuan. Over a longer timeframe, as of January 8, 2026, the ETF accumulated a 5.76% gain over the past week. (The stocks listed above are index constituents only and do not constitute specific recommendations.)

In terms of liquidity, Innovation Drug ETF recorded an intraday turnover rate of 1.31% and trading volume of 100 million yuan. Over a longer period, as of January 8, its average daily trading volume reached 458 million yuan over the past week, ranking among the top 2 comparable funds.

Scale-wise, Innovation Drug ETF's size grew 419 million yuan over the past two weeks, achieving significant growth and ranking 2nd out of 7 comparable funds in new scale increase. (Data source: Wind)

In terms of shares outstanding, the ETF's share count grew 60 million units over the past week, achieving significant growth and ranking 2nd out of 7 comparable funds in new share increase. (Data source: Wind)

Regarding capital flows, Innovation Drug ETF posted a latest net capital outflow of 115 million yuan. Over a longer timeframe, it attracted a total of 38.2167 million yuan over the past 4 trading days. (Data source: Wind)

Data shows leveraged funds continue to build positions. Innovation Drug ETF's latest margin purchase reached 42.6431 million yuan, with the latest margin balance at 320 million yuan. (Data source: Wind)

As of January 8, Innovation Drug ETF's NAV rose 14.62% over the past two years. In terms of return capability, as of January 9, 2026, since its inception, the ETF's highest monthly return was 23.00%, longest consecutive up months was 5, longest consecutive gain was 32.68%, average return in up months was 5.83%. As of January 9, 2026, its two-year excess return over benchmark reached 0.81% annualized.

On drawdowns, as of January 9, 2026, Innovation Drug ETF's year-to-date maximum drawdown was 0.00%, with a relative benchmark drawdown of 0.02%.

In terms of fees, Innovation Drug ETF charges a management fee of 0.50% and a custody fee of 0.10%.

Regarding tracking accuracy, as of January 9, 2026, Innovation Drug ETF's two-month tracking error was 0.011%, the highest tracking precision among comparable funds.

Innovation Drug ETF closely tracks the CSI Innovation Drug Industry Index. The CSI Innovation Drug Industry Index selects up to 50 most representative listed securities from companies whose main business involves innovation drug R&D as index samples to reflect the overall performance of innovation drug industry listed securities.

Industrial Securities stated that Chinese innovation drugs continue to strengthen their global competitiveness, with the past two years being a "big year" for innovation drug globalization, as outbound licensing deals reached record highs in both quantity and value. Following the closing of BD transactions, overseas Phase III clinical trials will be initiated. As listing certainty increases, valuations will rise (based on potential peak sales and improved success rates). Domestic demand-oriented CRO orders show simultaneous price and volume growth, benefiting from innovation drug BD globalization and the stabilization and recovery of financing, with project volume achieving double-digit growth. The 2026 performance cycle is expected to enter an improvement phase.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.